3 results
To determine non inferiority of two doses of BI 10773 (10 mg/daily and 25 mg/daily) compared to placebo with respect to first occurrence of any of the adjudicated components of the primary composite Major Adverse Cardiovascular Event endpoint (…
This study aims to investigate the effect of switching from Atripla® to Eviplera® on neurocognitive performances (neurocognitive testing) and imaging (functional MRI scanning) in virologically suppressed HIV-infected patients and stable on atripla.
Develop a fast metabolic MRI protocol, based on DMI and 31P-MRSI at ultra-high field MRI, to investigate the Warburg effect and phospholipid metabolism in glioblastoma and to asses metabolic disruption in epilepsy.